Systemic Sclerosis Trial Design Moving Forward

Area of Science:

• Rheumatology
• Clinical Trial Design
• Systemic Sclerosis Research

Background:

• The 2013 American College of Rheumatology/European League Against Rheumatism (ACR-EULAR) classification criteria have redefined systemic sclerosis (SSc).
• These revised criteria facilitate the inclusion of patients with less severe or advanced disease in clinical trials.
• This shift allows for a broader scope in therapeutic research.

Purpose of the Study:

• To highlight recent advances in research methodology for systemic sclerosis (SSc) trials.
• To broaden the considerations for designing and analyzing SSc clinical trials.
• To support the development of novel therapeutics targeting early-stage SSc.

Main Methods:

• Review of recent advances in clinical trial methodology.
• Discussion of design and analytic considerations for SSc trials.
• Focus on adapting trial strategies to the implications of the new classification criteria.

Main Results:

• The 2013 ACR-EULAR criteria enable recruitment of a wider spectrum of SSc patients.
• This allows for the investigation of disease-modifying therapies.
• Opportunities exist to prevent or mitigate organ involvement in early SSc.

Conclusions:

• The updated classification criteria for systemic sclerosis (SSc) necessitate a re-evaluation of clinical trial designs.
• Future trials can focus on early intervention to halt disease progression and prevent organ damage.
• Advances in research methodology support more effective SSc therapeutic development.